Ascendis Pharma logo

US Public Offering

USD 460 million
Co-Manager
;

Ascendis Pharma

Co-Manager

Kempen & Co acted as Co-Manager in Ascendis Pharma’s USD 460m Capital Increase

Transaction highlights

  • Public offering of 2,875,000 ADSs, corresponding to 2,875,000 underlying ordinary shares at a placement price of USD 160 per share, generating gross proceeds of USD 460 million
  • The placement price represents a premium of 2.1% vis-à-vis the closing price prior to transaction announcement, underscoring the high level of demand in the transaction
  • Ascendis Pharma intends to use the net proceeds to support clinical, regulatory and commercial activities regarding lonapegsomatropin-tcgd, to fund clinical development of its other endocrinology rare disease programs and to identify and develop new product candidates
  • Following our role as Co-Manager in Ascendis Pharma’s USD 690 million Capital Increase in July 2020, Kempen & Co is proud to have assisted this repeat client once again
  • In 2021 year to date, Kempen & Co has executed 20 Equity Capital Markets transactions, totalling USD 2.3 billion, for European life sciences companies listed across Europe and in the US

Company description

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and potentially best-in-class therapies. Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Background Kempen & Co Life Sciences & Healthcare

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Joint Bookrunner in the SEK 324 million Capital Increase by Calliditas Therapeutics
  • Joint Global Coordinator & Joint Bookrunner in the SEK 380 million Capital Increase by Xbrane Biopharma
  • Joint Global Coordinator in the €34.1m Capital Increase by Transgene
  • Joint Global Coordinator & Joint Bookrunner in the SEK 141 million Capital Increase by Immunicum
  • Lead Manager in the USD 63.8 million Nasdaq Initial Public Offering by Molecular Partners
  • Joint Bookrunner in the SEK 301 million Capital Increase by Q-linea
  • Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
  • Joint Bookrunner in the €30.0 million Capital Increase by GenSight Biologics
  • Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
  • Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
  • Joint Bookrunner in the SEK 1.11 billion Capital Increase by Oncopeptides
  • Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
  • Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
  • Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
  • Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
  • Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
  • Bookrunner in the USD 518 million US Public Offering by CureVac
  • Lead Manager in the USD 120 million US Public Offering by Merus 
  • Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
  • Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
  • Financial Adviser to DCprime in its merger with Immunicum 
  • Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
  • Lead Manager in the USD 95.1 million Nasdaq Initial Public Offering by Galecto
  • Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
  • Bookrunner in the USD 245 million Nasdaq Initial Public Offering by CureVac

Contact

Kathrin Erfurth
Nadine Maalouf

Transactions